Improving pediatric multiple sclerosis interventional phase III study design: a meta-analysis
CONCLUSION: This meta-analysis provides evidence that relapse rates are considerably higher with IFNs versus fingolimod or natalizumab. The results support the use of innovative Bayesian or non-inferiority designs to avoid exposing patients to less effective comparators in trials and bringing new medications to patients more efficiently.PMID:35514529 | PMC:PMC9066624 | DOI:10.1177/17562864211070449 (Source: Adv Data)
Source: Adv Data - May 6, 2022 Category: Epidemiology Authors: Jennifer S Graves Marius Thomas Jun Li Anuja R Shah Alexandra Goodyear Markus R Lange Heinz Schmidli Dieter A H äring Tim Friede Jutta G ärtner Source Type: research
GSE202087 Dissection of multiple sclerosis genetics identifies B and CD4+ T cells as driver cell subsets
Contributors : Michael H Guo ; Nikolaos A PatsopoulosSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensWe have performed ATAC-seq from FACS sorted immune cell populations from peripheral blood of human donors. All donors have a diagnosis of multiple sclerosis and some donors were treated with immunotherapy (glatiramer acetate, interferon beta, or natalizumab). We called peaks from the ATAC-seq data and tested for enrichment of open chromatin regions for each cell population in MS GWAS. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - May 6, 2022 Category: Genetics & Stem Cells Tags: Genome binding/occupancy profiling by high throughput sequencing Homo sapiens Source Type: research
Effectiveness and Safety of Early High-Efficacy Versus Escalation Therapy in Relapsing-Remitting Multiple Sclerosis in Argentina
Objective
Escalation (ES) and early high-efficacy (EHE) therapies have been the main treatment strategies adopted in multiple sclerosis (MS) in recent years. The aim of this study was to compare the effectiveness and safety of EHE versus ES strategies in MS patients from Argentina.
Methods
This is a retrospective multicenter cohort study in Argentina. Eligible patients were categorized into 2 groups as follows: EHE if received natalizumab, ocrelizumab, rituximab, alemtuzumab, mitoxantrone, or cladribine; and ES if received interferon β, glatiramer acetate, teriflunomide, dimethyl fumarate, or fingolimod as init...
Source: Clinical Neuropharmacology - May 1, 2022 Category: Neurology Tags: Original Articles Source Type: research
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | PMC:PMC9025511 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | PMC:PMC9025511 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | PMC:PMC9025511 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | PMC:PMC9025511 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | PMC:PMC9025511 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | PMC:PMC9025511 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | PMC:PMC9025511 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | PMC:PMC9025511 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | PMC:PMC9025511 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | PMC:PMC9025511 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
CONCLUSION: The neuropsychological impairment documented in this case study expands the range of treatment-related complications associated with natalizumab, and provides evidence that occurrence of "atypical" cognitive deficits in MS may support the early diagnosis of PML.PMID:35454389 | PMC:PMC9025511 | DOI:10.3390/medicina58040551 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 23, 2022 Category: Universities & Medical Training Authors: Viviana Lo Buono Giangaetano D'Aleo Simona Cammaroto Maria Cristina De Cola Francesca Palmese Chiara Smorto Silvia Marino Giuseppe Venuti Edoardo Sessa Carmela Rifici Francesco Corallo Source Type: research
